<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

Biodesix Receives CareFirst BlueCross BlueShield (BCBS) Coverage for VeriStrat Test

Diagnostic deemed medically necessary to guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC)

Biodesix, Inc. today announced that its VeriStrat® test received a positive coverage decision from CareFirst Blue Cross Blue Shield (BCBS).  CareFirst announced its position to extend coverage to the VeriStrat blood-based test for use as “a marker to aid in predicting patient response to EGFR-TKI drugs,” as described in the Health Care Policy section of BlueLink in March 2015, and published a positive coverage policy on April 20, 2015 on its website

VeriStrat is a blood-based proteomic test that provides physicians with prognostic and predictive information that helps guide treatment of advanced non-small cell lung cancer (NSCLC.) With test results reported in less than 72 hours, physicians can assess the patient’s VeriStrat profile just prior to making treatment decisions. VeriStrat testing was shown to be both cost effective and deliver cost savings in a health economics study published in Lung Cancer in April 2015; study results demonstrated that overall survival for patients with NSCLC improved by more than 1 month, and improved quality of life when making test-guided treatment decisions. A shift away from ineffective therapy for those patients with a test result of “poor” led to a reduction in the drug and drug administration costs alone of $4,098 per patient.

Lung cancer is the leading cause of cancer death in both women and men in the United States and in 2015 approximately 221,000 new cases of lung cancer are expected to be diagnosed. The need for precision medicine – to understand which lung cancer patients will respond to which therapies and, as a result, increase overall survival in this disease, is critical,”  said David Brunel, Biodesix’ CEO.  “This decision is great news for CareFirst BCBS’ members who can now be confident of coverage when their physicians choose VeriStrat to help guide their treatment decisions.”

CareFirst BCBS, which covers patients in Maryland, the District of Columbia, and portions of Virginia, has a membership of 3.4 million people, and is the largest health-care insurer in the Mid-Atlantic region. CareFirst’s policy can be found at https://provider.carefirst.com/providers/medical/medical-policy.page

VeriStrat and Biodesix are registered trademarks of Biodesix, Inc.  All other trademarks referenced herein are the property of their respective owners.

About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative blood-based tests in oncology for precision medicine. VeriStrat® is a commercially available multivariate serum protein test for both predictive and prognostic utility in advanced NSCLC.  The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which can lead to improved patient outcomes.  Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic tests on various discovery platforms. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents.

For more information about Biodesix, please visit www.Biodesix.com.

MEDIA CONTACT:

Patrick French

1-858-457-2436

Biodesix@Chempetitive.com

For Customer Support, call: (866) 432-5930

Topics: Press Releases